Código QR (código de barras bidimensional)

Real-World Outcomes of Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia

Background: Chronic lymphocytic leukemia (CLL) is a biologically heterogeneous disease characterized by variable clinical outcomes. The introduction of targeted therapies, particularly the BCL-2 inhibitor venetoclax, has significantly improved treatment outcomes in patients with relapsed/refractory...

ver descrição completa

Na minha lista:
Principais autores: Asli Odabasi Giden, Duzgun Ozatli, Mehmet Ali Erkurt, Abdullah Karakus, Gulden Sincan, Fehmi Hindilerden, Yusuf Bilen, Ugur Hatipoglu, Gulsum Akgun Cagliyan, Tuba Hacibekiroglu, Sinan Demircioglu, Didar Yanardag Acik, Cengiz Demir, Yavuz Katircilar, Anil Tombak, Seda Yilmaz, Irfan Kuku, Fuat Erdem, Asli Yuksel Ozturkmen, Mehmet Sinan Dal, Semih Basci, Serdal Korkmaz, Turgay Ulas, Fevzi Altuntas
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI AG 2026-05-01
coleção:Hemato
Assuntos:
chronic lymphocytic leukemia
venetoclax
relapsed/refractory
real-world data
BCL-2 inhibitor
tumor lysis syndrome
Acesso em linha:https://www.mdpi.com/2673-6357/7/2/16
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados